RU2351595C2 - N-гидроксиформамидные соединения в качестве ингибиторов металлопротеиназ - Google Patents

N-гидроксиформамидные соединения в качестве ингибиторов металлопротеиназ Download PDF

Info

Publication number
RU2351595C2
RU2351595C2 RU2005141058/04A RU2005141058A RU2351595C2 RU 2351595 C2 RU2351595 C2 RU 2351595C2 RU 2005141058/04 A RU2005141058/04 A RU 2005141058/04A RU 2005141058 A RU2005141058 A RU 2005141058A RU 2351595 C2 RU2351595 C2 RU 2351595C2
Authority
RU
Russia
Prior art keywords
mmol
compound
compounds
formula
phenyl
Prior art date
Application number
RU2005141058/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005141058A (ru
Inventor
Морис Реймонд Версчойл ФИНЛЕЙ (GB)
Морис Реймонд Версчойл ФИНЛЕЙ
Дейвид УОТЕРСОН (GB)
Дейвид УОТЕРСОН
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2351595(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2005141058A publication Critical patent/RU2005141058A/ru
Application granted granted Critical
Publication of RU2351595C2 publication Critical patent/RU2351595C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
RU2005141058/04A 2003-06-27 2004-06-23 N-гидроксиформамидные соединения в качестве ингибиторов металлопротеиназ RU2351595C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922-1 2003-06-27
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (2)

Publication Number Publication Date
RU2005141058A RU2005141058A (ru) 2006-07-27
RU2351595C2 true RU2351595C2 (ru) 2009-04-10

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005141058/04A RU2351595C2 (ru) 2003-06-27 2004-06-23 N-гидроксиформамидные соединения в качестве ингибиторов металлопротеиназ

Country Status (33)

Country Link
US (1) US7485644B2 (OSRAM)
EP (1) EP1644340B1 (OSRAM)
JP (1) JP4701167B2 (OSRAM)
KR (1) KR20060026440A (OSRAM)
CN (2) CN102229589A (OSRAM)
AR (1) AR044931A1 (OSRAM)
AT (1) ATE414063T1 (OSRAM)
AU (1) AU2004251104B2 (OSRAM)
BR (1) BRPI0411929A (OSRAM)
CA (1) CA2529468A1 (OSRAM)
CO (1) CO5650254A2 (OSRAM)
CY (1) CY1108757T1 (OSRAM)
DE (1) DE602004017733D1 (OSRAM)
DK (1) DK1644340T3 (OSRAM)
ES (1) ES2315675T3 (OSRAM)
HR (1) HRP20090009T3 (OSRAM)
IL (1) IL172615A0 (OSRAM)
IS (1) IS8257A (OSRAM)
MX (1) MXPA05013460A (OSRAM)
MY (1) MY138680A (OSRAM)
NO (1) NO20060444L (OSRAM)
NZ (1) NZ544208A (OSRAM)
PL (1) PL1644340T3 (OSRAM)
PT (1) PT1644340E (OSRAM)
RU (1) RU2351595C2 (OSRAM)
SA (1) SA04250224B1 (OSRAM)
SE (1) SE0301922D0 (OSRAM)
SI (1) SI1644340T1 (OSRAM)
TW (1) TW200524898A (OSRAM)
UA (1) UA81491C2 (OSRAM)
UY (1) UY28387A1 (OSRAM)
WO (1) WO2005000822A1 (OSRAM)
ZA (1) ZA200510458B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2569851C2 (ru) * 2010-07-08 2015-11-27 Какен Фармасьютикал Ко., Лтд. Производное n-гидроксиформамида и содержащее его лекарственное средство

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
RS52229B (sr) * 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038843A1 (en) * 1998-01-30 1999-08-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2000012478A1 (en) * 1998-08-31 2000-03-09 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
WO2000075108A1 (en) * 1999-06-04 2000-12-14 Astrazeneca Uk Limited Inhibitors of metalloproteinases
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
WO2003014092A1 (en) * 2001-08-09 2003-02-20 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309671A (pt) * 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
JP2006527754A (ja) * 2003-06-19 2006-12-07 セルテック アール アンド ディ リミテッド Ｃｄ２３分断阻害物質としてのヒドロキサム酸スルホンアミド

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038843A1 (en) * 1998-01-30 1999-08-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2000012478A1 (en) * 1998-08-31 2000-03-09 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
WO2000075108A1 (en) * 1999-06-04 2000-12-14 Astrazeneca Uk Limited Inhibitors of metalloproteinases
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
WO2003014092A1 (en) * 2001-08-09 2003-02-20 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2569851C2 (ru) * 2010-07-08 2015-11-27 Какен Фармасьютикал Ко., Лтд. Производное n-гидроксиформамида и содержащее его лекарственное средство

Also Published As

Publication number Publication date
US20070197542A1 (en) 2007-08-23
PT1644340E (pt) 2009-01-02
IL172615A0 (en) 2006-04-10
DE602004017733D1 (de) 2008-12-24
CN102229589A (zh) 2011-11-02
SE0301922D0 (sv) 2003-06-27
TW200524898A (en) 2005-08-01
ATE414063T1 (de) 2008-11-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
HK1086835A1 (en) 2006-09-29
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
CY1108757T1 (el) 2014-04-09
AU2004251104B2 (en) 2008-05-08
MXPA05013460A (es) 2006-03-09
PL1644340T3 (pl) 2009-04-30
JP4701167B2 (ja) 2011-06-15
CO5650254A2 (es) 2006-06-30
MY138680A (en) 2009-07-31
BRPI0411929A (pt) 2006-08-15
WO2005000822A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
CN1812974B (zh) 2011-06-29
ES2315675T3 (es) 2009-04-01
JP2007516164A (ja) 2007-06-21
AR044931A1 (es) 2005-10-12
IS8257A (is) 2006-01-23
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DK1644340T3 (da) 2009-02-02
UY28387A1 (es) 2005-01-31
EP1644340B1 (en) 2008-11-12
RU2005141058A (ru) 2006-07-27
HRP20090009T3 (en) 2009-02-28
AU2004251104A1 (en) 2005-01-06
UA81491C2 (en) 2008-01-10
EP1644340A1 (en) 2006-04-12
KR20060026440A (ko) 2006-03-23
US7485644B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
CN101541789B (zh) 用作基质金属蛋白酶抑制剂的乙内酰脲衍生物
KR101280095B1 (ko) 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
RU2388758C2 (ru) Производные гидантоина, полезные в качестве ингибиторов металлопротеиназ
JP4701167B2 (ja) メタロプロテイナーゼ阻害剤としてのｎ−｛（４−置換ピペラジン−１−スルホニルメチル）アルキル｝−ｎ−ヒドロキシホルムアミド化合物
WO2004024060A2 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
HK1086835B (en) N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors
HK1108435B (en) Hydantoin derivatives useful as metalloproteinase inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130624